糖尿病、胰岛素与二甲双胍使用对人表皮生长因子受体2阳性原发性乳腺癌患者结局的影响:ALTTO III期随机试验分析
ALTTO III期随机试验纳入8381例HER2阳性原发性乳腺癌患者,评估入组时糖尿病及二甲双胍治疗与无病生存(DFS)、远处无病生存(DDFS)和总生存(OS)的关联。中位随访4.5年,未接受二甲双胍治疗的糖尿病患者DFS、DDFS和OS均更差,该效应限于激素受体阳性患者;胰岛素治疗与不利影响相关,而二甲双胍在HER2阳性且激素受体阳性糖尿病患者中显示有益效应。
要点
- 入组时未接受二甲双胍治疗的糖尿病患者DFS、DDFS和OS均更差。
- 该不良预后效应仅限于激素受体阳性患者。
- 胰岛素治疗与不利影响相关,二甲双胍在HER2阳性且激素受体阳性糖尿病患者中显示有益效应。
核心结论
- 二甲双胍可能改善与糖尿病和胰岛素治疗相关的不良预后,主要见于原发性HER2阳性且激素受体阳性乳腺癌患者。
研究设计与样本
- ALTTO III期随机试验将HER2阳性乳腺癌患者随机分配接受1年曲妥珠单抗单药、拉帕替尼单药、两者序贯或两者联合治疗。
- 本亚组分析纳入8381例患者,评估入组时糖尿病(伴或不伴二甲双胍治疗)与无糖尿病患者的DFS、DDFS和OS差异。
- 中位随访4.5年(范围0.16至6.31年)。
主要发现
- 随访期间共1205例(14.38%)发生DFS事件,929例(11.08%)发生DDFS事件,528例(6.3%)发生OS事件。
- 未接受二甲双胍治疗的糖尿病患者DFS更差(多变量HR 1.40;95%CI 1.01至1.94;P=0.043)。
- 未接受二甲双胍治疗的糖尿病患者DDFS更差(多变量HR 1.56;95%CI 1.10至2.22;P=0.013)。
- 未接受二甲双胍治疗的糖尿病患者OS更差(多变量HR 1.87;95%CI 1.23至2.85;P=0.004)。
- 该效应仅限于激素受体阳性患者;胰岛素治疗与不利影响相关,二甲双胍在HER2阳性且激素受体阳性糖尿病患者中显示有益效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Previous studies have suggested an association between metformin use and improved outcome in patients with diabetes and breast cancer. In the current study, we aimed to explore this association in human epidermal growth factor receptor 2 (HER2 ) -positive primary breast cancer in the context of a large, phase III adjuvant trial. Patients and Methods The ALTTO trial randomly assigned patients with HER2-positive breast cancer to receive 1 year of either trastuzumab alone, lapatinib alone, their sequence, or their combination. In this substudy, we evaluated whether patients with diabetes at study entry-with or without metformin treatment-were associated with different disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS) compared with patients without diabetes. Results A total of 8,381 patients were included in the current analysis: 7,935 patients (94.7%) had no history of diabetes at diagnosis, 186 patients (2.2%) had diabetes with no metformin treatment, and 260 patients (3.1%) were diabetic and had been treated with metformin. Median follow-up was 4.5 years (0.16 to 6.31 years), at which 1,205 (14.38%), 929 (11.08%), and 528 (6.3%) patients experienced DFS, DDFS, and OS events, respectively. Patients with diabetes who had not been treated with metformin experienced worse DFS (multivariable hazard ratio [HR], 1.40; 95% CI, 1.01 to 1.94; P = .043), DDFS (multivariable HR, 1.56; 95% CI, 1.10 to 2.22; P = .013), and OS (multivariable HR, 1.87; 95% CI, 1.23 to 2.85; P = .004). This effect was limited to hormone receptor-positive patients. Whereas insulin treatment was associated with a detrimental effect, metformin had a salutary effect in patients with diabetes who had HER2-positive and hormone receptor-positive breast cancer. Conclusion Metformin may improve the worse prognosis that is associated with diabetes and insulin treatment, mainly in patients with primary HER2-positive and hormone receptor-positive breast cancer.
引用
- Sonnenblick A, Agbor-Tarh D, Bradbury I, et al. Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. J Clin Oncol. 2017. PMID: 28375706. doi:10.1200/JCO.2016.69.7722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。